An Educational Intervention to Improve Statin Use: Cluster RCT at the Primary Care Level in Argentina

GULAYIN, PABLO E.; GUTIERREZ, LAURA; SANTERO, MARILINA; IRAZOLA, VILMA; BERATARRECHEA, ANDREA; CHAPARRO, RAÚL MARTÍN; RUBINSTEIN, ADOLFO; LOZADA, ALFREDO; POGGIO, ROSANA; MASSON, WALTER; GULAYIN, PABLO E.; GUTIERREZ, LAURA; SANTERO, MARILINA; IRAZOLA, VILMA; BERATARRECHEA, ANDREA; CHAPARRO, RAÚL MARTÍN; RUBINSTEIN, ADOLFO; LOZADA, ALFREDO; POGGIO, ROSANA; MASSON, WALTER

AMERICAN JOURNAL OF PREVENTIVE MEDICINE.

ELSEVIER SCIENCE INC

Año: 2019 vol. 57 p. 95 - 105

0749-3797

Introduction: Statins are essential drugs for high cardiovascular disease (CVD) risk management; however, there is still low adherence to good clinical practice guidelines for statin use at the primary care level in low- and middle-income countries. This study aimed to test whether a complex intervention targeting physicians improves treatment and control of hypercholesterolemia among patients with moderate to high CVD risk in Argentina. Study design: Cluster RCT. Setting/participants: Ten primary care centers from the public healthcare system of Argentina. Intervention: Primary care physicians in the intervention group received an educational program with three main components: (1) an intensive 2-day training workshop; (2) educational outreach visits; and (3) a mobile health application installed on the physician´s smartphones. Main outcome measures: Reduction in mean low-density lipoprotein cholesterol level, reduction in mean Framingham risk score, proportion of patients receiving an appropriate statin dose, and mean annual number of primary care center visits. Results: Data were analyzed in 2017?2018. Between April 2015 and April 2016, a total of 357 participants were enrolled (179 patients in the intervention group and 178 in the control group). The global follow-up rate was 97.2%. At the end of the follow-up period, there was no difference in low-density lipoprotein cholesterol levels in any of the follow-up points among the groups. Mean CVD risk had a significant net difference in the first 6 months in the intervention group versus the control group (?4.0, 95% CI = ?6.5, ?1.5). At the end of follow-up, there was an absolute 41.5% higher rate of participants receiving an appropriate statin dose in the intervention group versus the control group. Conclusions: Although the intervention did not reach a reduction in cholesterol levels, it had a significant positive impact on the promotion of adequate use of clinical practice guidelines. Trial registration: This study is registered at www.clinicaltrials.gov NCT02380911.